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Lichen planus (LP) is a chronic inflammatory disorder thatmost often affectsmiddle-aged adults. LP can involve the skin ormucous
membranes including the oral, vulvovaginal, esophageal, laryngeal, and conjunctival mucosa. It has different variants based on the
morphology of the lesions and the site of involvement. The literature suggests that certain presentations of the disease such as
esophageal or ophthalmological involvement are underdiagnosed. The burden of the disease is higher in some variants including
hypertrophic LP and erosive oral LP, whichmay have amore chronic pattern. LP can significantly affect the quality of life of patients
as well. Drugs or contact allergens can cause lichenoid reactions as the main differential diagnosis of LP. LP is a T-cell mediated
immunologic disease but the responsible antigen remains unidentified. In this paper, we review the history, epidemiology, and
clinical subtypes of LP. We also review the histopathologic aspects of the disease, differential diagnoses, immunopathogenesis, and
the clinical and genetic correlations.
1. Introduction
Lichen planus (LP) is a chronic inflammatory and immune
mediated disease that affects the skin, nails, hair, and mucous
membranes. Cutaneous lichen planus (CLP)most commonly
involves the flexor surfaces of the extremities and presents
as small itchy violaceous Papules in middle-aged adults.
“Pruritic, Purple, Polygonal, Planar, Papules, and Plaques”
are the traditional 6 “P’s” of LP [1]. The lesions are typically
bilateral and relatively symmetric. Oral LP (OLP) can be
the sole clinical presentation of the disease or accompanied
by cutaneous or other mucosal manifestations including the
genital area, gastrointestinal tract, and eyes.
2. Materials and Methods
In this paper, we review the different aspects of LP, including
history, epidemiology, clinical subtypes, histopathologic fea-
tures, differential diagnoses, immunopathogenesis, clinical
and genetic correlations, quality of life, and prognosis of the
disease. We searched the literature using terms: “lichen” and
“planus.”
3. Results and Discussion
3.1. History. LP (Greek “Leichen” = tree moss, Latin “planus”
= flat, even) [2] was first explained in 1869 by Dr. Wilson as
an inflammatory disorder of the stratified squamous epithelia
with an unknown etiology. Dr. Wilson probably referred
to the condition that was originally described by Herba as
“Lichen ruber” [3, 4]. It was originally named “lichen ruber
planus” and “lichen psoriasis” [5]. Weyl initially described
the characteristic surface markings on LP Papules, known as
Wickham striae, in 1885 [6], and Wickham explained it fur-
ther in 1895 [7]. Darier correlated the presence of Wickham’s
striae with an increase in thickness of the granular cell layer
[8]. In 1937, Guogerot and Burnier described the coexistence
of oral, cervical, and stomach LP lesions with no cutaneous
involvement as “plurimucosal LP” [9]. In 1982, Pelisse and
colleagues reintroduced a similar variant of mucosal LP
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as the vulvovaginal-gingival syndrome with erosive lesions
involving the oral and vulvovaginal mucosa [10].
3.2. Epidemiology. The exact prevalence of LP is unknown.
Nevertheless, the estimated prevalence of LP is in the range of
0.22% to 5% worldwide [11–15]. The epidemiological studies
lack clear diagnostic criteria or a uniformmethodology. Fur-
thermore, the diverse clinical presentation and the asymp-
tomatic nature of the most common subtype of OLP make
the disease an underdiagnosed health issue [16]. McCartan
and Healy [17] identified forty-five studies that calculated the
prevalence or incidence of LP.They concluded an overall age-
adjusted prevalence of 1.27% (0.96% in men and 1.57% in
women) in Sweden [14, 18].The incidence of LP was 0.032%–
0.037% in a British population [19]. LP typically affects
middle-aged adults of both genders. No sexual predilection
is evident but some reports indicate a slight predominance in
women up to a ratio of 2 : 1 [20]. Interestingly, in the top 3
largest case series of childhood LP, the female to male ratio is
reported to be 1 : 2 in a US population [21], 1 : 1.5 in an Indian
cohort [22], and 2 : 1 in a Canadian study [23]. Such variability
may be explained by different inclusion and exclusion criteria
within the studies. The relative male predilection in child-
hood LP is unusual for an autoimmune disease and suggests
that other possible unknownmechanismsmay be involved in
the pathogenesis of LP. Childhood LP is more common in the
African American population [23]. Moreover, hypertrophic
and actinic variants as well as LP pigmentosus are more
prevalent amongst African Americans or darker skinned
individuals [2, 24, 25]. Postinflammatory hyperpigmentation
is a characteristic outcome of LP lesions that is predominantly
more common in the African American population [2].
Asians acquire the follicular form less frequently than the
other ethnicities according to a Canadian epidemiological
study [26].
3.3. Clinical Subtypes
3.3.1. CLP. CLP has different clinical subtypes based on the
morphology of the lesions and the site of involvement.
Subtypes Based onConfiguration orMorphology of the Lesions.
They include papular (classic), hypertrophic, vesiculobullous,
actinic, annular, atrophic, linear, follicular, LP pigmentosus
and LP pigmentosus-inversus.
The classic CLP lesion is a shiny, red/purple-colored, flat-
topped papule (Figure 1(a)). Lesions may also have a thin,
transparent, and adherent scale. Wickham’s striae, which are
defined as fine whitish points or lacy lines, may be seen on
the surface of well-developed Papules [27].
Hypertrophic LP is characterized by hyperkeratotic thick
pruritic red-brown to purple-gray plaques with follicular
accentuation [28] that commonly involves the extremities,
especially the anterior legs and the interphalangeal joints
in a symmetrical distribution (Figure 1(b)) [2]. Welsh et al.
described its resemblance to the extrusive forms of igneous
rock as a useful sign in distigushing the hypertrophic subtype
fromother differential diagnoses [28]. Polygonal Papulesmay
be seen surrounding the main lesion.
In the vesiculobullous subtype, blisters develop within
the plaques (Figure 1(c)). Lower extremities are the main
site of involvement. This pattern of the disease has to be
distinguished from LP pemphigoides, a rare coexistence of
LP and bullous pemphigoid [29].
Actinic CLP is a rare subtype presenting as nummular
patches or plaques with a hypopigmented halo surrounding
a hyperpigmented center (Figure 1(d)). This variant is more
prevalent inAfricanAmericans, Indians, andMiddle-Eastern
individuals and affects the sun-exposed areas [30, 31].
Annular CLP is an uncommon form that classically
involves the male genitalia (glans penis and penile shaft) and
also axilla, groin, and extremities (Figure 1(e)) [32]. Although
CLP usually presents with pruritus, the annular form is often
asymptomatic especially when arising in the genital area [33].
Atrophic CLP is the clinical endpoint of chronic annular
or hypertrophic LP with atrophic lesions (Figure 1(f)) [34].
Diagnosis may be difficult unless classic LP is present else-
where on the body. The anatomical distribution of lesions
may be helpful as it mainly affects the same areas that are
involved in the annular or hypertrophic variants. Long-term
use of potent or superpotent topical corticosteroids may
predispose the patient to developing atrophic lesions.
Linearly oriented lesions of CLP can be caused by the
Koebner phenomenon, but this pattern is not considered as
the true linear form. The true linear form is more extensive
and follows the lines of Blashko [35]. In rare circumstances,
if linear LP presents in a dermatomal pattern, it is called
zosteriform LP (Figure 1(g)) [36]. This rare variant is found
either at the site of healed herpes zoster lesions (Wolf isotopic
response) or de novo in normal skin. The exact etiology of
the zosteriform subtype remains debatable [37]. The isotopic
response can also occur in the annular subtype [38].
LP pigmentosus is usually seen in Indians and darker
skinned individuals. Lesions are characteristically bilat-
eral and involve sun-exposed areas [24]. Conversely, LP
pigmentosus-inversus was reported in whites and lighter-
skinned Asians, which typically affects the intertriginous and
flexural areas [39, 40].
Classic follicular CLP, fibrosing alopecia in a pattern
distribution, frontal fibrosing alopecia (FFA), and Graham
Little-Piccardi-Lassueur syndrome [41]. The typical form of
LPP is characterized by pinpoint hyperkeratotic Papules often
found on the scalp. It frequently affects the vertex but can
also involve other parts of the scalp [42]. LPP has a sexual
predilection for females and can involve nail and mucosa
[43, 44]. LPP can also be induced by hair transplantation
or face-lift surgery. The possible triggering factors include
the Koebner phenomenon, perisurgery antigen release, or
the postoperative immune-inflammatory response [45, 46].
“Fibrosing alopecia in a pattern distribution” is another
suggested subtype that has a centroparietal pattern. It lacks
the multifocal scarring of classic LPP and can be discerned
accordingly [47]. FFA is more commonly seen in post-
menopausal women. The pattern of alopecia is analogous to
male pattern androgenetic alopecia with frontal dominance
and additional features such as scarring and a lichenoid
pattern on histopathology [48]. Graham Little-Piccardi-
Lassueur syndrome is a rare variant of LPP characterized
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Figure 1: (a) Classic CLP: violaceous Papules on the dorsal hand and volar wrist (courtesy of Dr. Omid Zargari); (b) hypertrophic CLP:
centrally eroded hyperkeratotic plaques involving the lower leg; (c) vesiculobullous CLP: vesicles and bullae on right and left ankles and
lower legs (courtesy of Dr. Peter Lynch); (d) actinic CLP: hyperpigmented Papules and plaques on the dorsal hands (courtesy of Dr. Peter
Lynch); (e) annular CLP: reticulated white striae involving the glans penis (courtesy of Dr. Omid Zargari); (f) atrophic CLP: hyperpigmented
macules and patches on the arm (courtesy of Dr. Peter Lynch); (g) zosteriform CLP: linearly oriented confluent violaceous Papules on the
arm; (h) nail CLP: longitudinal ridging of the fingernails (courtesy of Dr. Peter Lynch); (i) nail CLP: dorsal pterygium of the thumbnail; (a),
(b), (e), (g), and (i) are reprinted with permission from [50]. CLP, cutaneous lichen planus.
by the triad of follicular-based spinous Papules on the body,
scalp, or both, patchy cicatricial alopecia of the scalp, and
noncicatricial alopecia of the axilla and pubic region. It is
preferentially more common in females [49].
Lichen Planus Subtypes Based on the Site of Involvement.
Palmoplantar LP is a rare subtype. The erythematous scaly
form is the most common clinical presentation. The lesions
are multiple (more than 10 lesions), bilateral, and often
symmetrical with prominent associated pruritus. The most
common sites of involvement include the malleoli and also
the internal plantar arch [51]. Fingertips are often spared.The
second most common clinical form presents as hyperkera-
totic plaques [51]. Palmoplantar LP can less frequently present
as vesiculobullous lesions [52].
The scalp is the main site of follicular CLP or LPP as
described above.
LP causes nail lesions in 1–10% of adult cases
(Figures 1(h) and 1(i)). Nail LP is more commonly seen
in children [53]. One study reported a prevalence of 19% in
a cohort of 100 childhood LP cases from India [22]. Tosti
and coworkers noted that nail LP may be underdiagnosed
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Figure 2: (a) Reticular OLP: reticulated white striae of the lower lip proper; (b) plaque-type OLP: confluent white reticulated plaques of
the lateral tongue; (c) erosive OLP: superficial erosions and white striae of the lower lip proper (courtesy of Dr. Peter Lynch); (d) vulvar
LP: superficial erosions at the vulvar introitus with fusion of the labia minora and vaginal stenosis; Figures 1(a) and 1(b) are reprinted with
permission from [50]. OLP, oral lichen planus.
in children because of the fact that isolated nail lesions are
more common in this age group [53]. Likewise, Kanwar and
De suggested that the general hesitation of dermatologists
to perform nail biopsies on children may be another reason
for underdiagnosis of the disease in this age group [22].
Fingernails are more commonly involved than toenails [54].
Although it can affect both the nail matrix and the nail bed,
the diagnosis of classic nail LP should be based on destruction
of the nail bed with longitudinal fissuring and ridging of
the nail plate, brittleness (onychorrhexis) and spontaneous
separation of the nail plate (onycholysis) [53, 55, 56]. Nail
involvement may irreversibly deform or destroy the nails.
Dorsal pterygium is one of the characteristic findings and
may be present in the classic form [53, 57]. Twenty-nail
dystrophy is characterized by nail coarseness affecting all
fingernails and toenails because of excessive longitudinal
ridging (trachyonychia). This clinical presentation is
observed in LP as well as other diseases that involve the
nail matrix such as alopecia areata, psoriasis, eczema, and
pemphigus vulgaris [53]. In rare circumstances, localized
distal subungual hyperkeratosis withmultinucleated cells can
arise (onychopapilloma) [58]. Additionally, melanonychia
can be induced with resolution of the lesions [59].The lunula
may be irregularly red in a focal or disseminated pattern due
to the associated inflammation. In the toenails, remarkable
thickening may be noted and can be mistaken with yellow
nail syndrome. Furthermore, erosive nail LP may rarely
occur with painful erosions and consequent scarring [54].
Another rare variant, idiopathic atrophy of the nails, can
cause rapid diffuse nail atrophy and pterygium of the nails
and can ultimately lead to permanent anonychia [54].
3.3.2. Mucosal LP. Mucosal LP more commonly involves the
oral mucosa but can also affect the vulvovaginal area. LP
can rarely manifest in the esophagus, larynx, and conjunctiva
[60].
OLP. OLP has several clinical subtypes including reticular,
erosive, atrophic, papular, plaque-like, and bullous subtypes.
Figures 2(a)–2(c) illustrate different subtypes of OLP. The
buccal mucosa is typically involved in 80–90% of OLP cases.
The Koebner phenomenon is not only present in CLP but
can also occur in the setting of OLP. Eisen [20] suggested
that the mechanical trauma of dental procedures, cigarette
smoking, mucosal trauma from sharp cusps, and oral habits
such as lip chewing are Koebnerogenic factors that can
exacerbate OLP. Reticular OLP, the most common subtype,
is usually asymptomatic. Hence, it is often diagnosed during
a routine oral examination. Reticular OLP is characterized by
white lacy streaks surrounded by well-defined erythematous
borders. This pattern is less evident on the dorsum of the
tongue [61]. In some patients, reticular OLP may eventually
progress to themore severe subtypes such as the erosive form.
Papular OLP is characterized by small white pinpoint Papules
that can be easily missed as they are small and asymptomatic.
It is referred to as the initial and transient phase of OLP [62].
That is why it is a rare diagnosis [63, 64]. In plaque-like OLP,
large, homogenous white patches are characteristic. Plaque-
like OLP and leukoplakia have similar clinical presentations
and therefore leukoplakia must always be ruled out [64].
This variant is more prevalent in tobacco smokers [62]. The
existence of plaque-like lesions is an indicator of a poor
prognosis and a lesser likelihood of remission [62]. Erosive
OLP, the most advanced subtype, can clinically present as
atrophic or erythematous ulcerations and erosions of the
mucosa and faint radiating white striae.The associated ulcers
are sometimes covered with a pseudomembrane. Typically,
it has a multifocal pattern of distribution. It is clinically
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important because the lesions can be quite painful and
therefore it may negatively affect the patient’s quality of
life. The symptoms may range from discomfort to severe,
painful episodes. Involvement of the dorsum of the tongue
might cause dysgeusia [16]. The atrophic subtype is common
presentation that has similarities to the erosive subtype
with more prominent atrophic lesions on a background of
erythema and radiating white striae at the margins. Thus,
some experts combine the two entities and name it atrophic-
erosive lichen planus. This subtype is more common in
older OLP patients [62]. Atrophic OLP primarily affects
the attached gingiva [64]. The buccal mucosa can also be
involved, particularly in the posteroinferior areas adjacent to
the second and third molar teeth [65]. In rare instances, OLP
may present with bullous lesions. Lourenc¸o and colleagues
suggested a rare form of OLP as “Lichen planus sialadenitis,”
a mucosal analog of LPP due to lymphocyte infiltration in the
salivary gland ducts [66].
Vulvovaginal LP. Vulvar LP can affect peri- or post-
menopausal women with rare occurrence in children [67].
Vulvovaginal LP has a similar pattern to OLP. Figure 2(d)
illustrates vulvar LP. It has three major subtypes: erosive,
papulosquamous, and hypertrophic [68]. Erosive vulvar LP is
themost frequent subtype, involving themucousmembranes
exclusively [69]. The most significant sequelae of chronic
erosive vulvar LP are scarring, which can result in resorption
of the labia minora (agglutination) and clitoral hood, with
subsequent clitoral burying (synechiae, 68%), stenosis of
the introitus (59%), and potentially total obliteration of the
vagina. The associated scarring and adhesions affecting the
vagina may interfere with sexual intercourse [70, 71]. It is
essential to consider the patient’s psychological status and
quality of life, which can be deeply affected by the disease.
Sexual abstinence or dyspareunia was present in 46 out of
58 patients diagnosed with genital erosive LP referred to a
specialized center in Norway over a 7-year period [72]. It is
also beneficial to document the extent and location of the
lesions in the vulva and examine other mucocutaneous sites
of LP at each visit [73]. In addition to dyspareunia, vulvar LP
can lead to symptoms of intense pruritus with chronic vaginal
discharge, burning, and postcoital bleeding [72, 74]. The
presentation of papulosquamous and hypertrophic vulvar LP
is similar to their correspondingOLP subtypes. Furthermore,
43%–100% [60, 70, 73] of vulvar cases may have concomitant
oral involvement, whereas about 25% of OLP patients may
have vulvar involvement [20]. The coexistence of oral and
genital lesions is known as vulvovaginal-gingival syndrome
[75]. Skin lesions are as frequent as 17%–22% in this syndrome
[60, 73].
Esophageal LP. LP of the esophagus is a rare presentation
of the disease. It is an underdiagnosed and underreported
entity with a sexual predilection in women [76]. In the
majority of cases, esophageal LP may be accompanied by
other mucosal lesions or less commonly concomitant with
cutaneous manifestations. It may also present as an isolated
disease in its initial presentation (20%). Ultimately, extrae-
sophageal lesions can be found in almost all patients with
esophageal LP [76]. The proximal esophagus is affected in
90%of caseswith orwithout distal involvement. Inmay cases,
there is a significant delay between the onset of symptoms and
detection of esophageal involvement. Thyroid dysfunction
is the most common associated disorder [76]. In a case-
control study, superficial gastritis was significantly more
common in LP patients than healthy controls [77].Therefore,
it is important to consider upper GI endoscopy particularly
in LP patients with complaints of dysphagia, odynophagia,
weight loss, or other esophageal symptoms and those with
involvement of other mucosal surfaces [78].
Ocular LP. LP may be accompanied by significant ophthal-
mologic problems including a decrease in tear production
[79]. More than one third of LP patients have blepharitis [79].
S¸anli and coworkers also noted a lower number of goblet
cells in the conjunctival epithelium of LP patients, when
compared to controls [79]. Ocular involvement may also
causemild tomoderate xerophthalmia and occasionally cica-
tricial conjunctivitis [79, 80]. Conjunctival involvement can
start with white streaks involving the palpebral conjunctiva
[80]. In a case series of 9 LP patients with ophthalmological
signs, 7 cases had vulvovaginal-gingival syndrome and all
patients developed subepithelial fibrosis and lacrimal duct
stenosis [81]. Webber et al. recommended ophthalmologic
evaluation and examination of the lacrimal duct puncta in
erosive LP patients [81]. Other ophthalmologic signs include
eyelid lesions [82, 83], keratouveitis [80], keratoconjunctivitis
sicca [80], punctate epithelial erosions [80, 84], corneal
ulceration/scarring [84], and dysplastic conjunctival lesions
resembling ocular surface squamous neoplasia [85]. LP was
also reported as chronic keratoconjunctivitis with diffuse
conjunctival hyperemia, subconjunctival fibrosis, and for-
niceal symblephara with foreshortening of the lower fornix
in the isolated ocular form [86]. This form of the disease
can be a diagnostic challenge [87]. Biopsy for histopathologic
examination and immunofluorescence studies is the only way
to differentiate ocular LP from other causes of irreversible
scarring keratoconjunctivitis [86].The presence of subepithe-
lial fibrinogen is not necessarily inclusive of any particular eye
disease on immunofluorescence analysis, but a fragmented
and shaggy subepithelial fibrinogen layer in the conjunctiva
is indicative of LP [88, 89]. It is essential to diagnose and
treat such disease quickly and efficiently to avoid the dire
consequences of blindness [90].
Laryngeal LP. Involvement of the larynx is extremely rare.
In fact, few patients with laryngeal LP have been reported
[91–93]. The first case was a 57-year-old Caucasian man
with isolated laryngeal LP and complaints of hoarseness
[91]. The second case was an 18-year-old Pakistani man with
mucosal LP in the mouth, conjunctivae, and larynx [92].
Kunelskaya Ya. and Arievich reported the largest case series
of laryngeal involvement in 8 mucosal LP patients. They
noted involvement of epiglottis and aryepiglottic folds but
no involvement of vocal cords. The lesions were larger in the
epiglottis region than other parts of the larynx [93].
Table 1 addresses the most common sites of involvement
for LP subtypes.
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Table 1: The most common sites of involvement in LP based on subtypes.
Subtypes Most common sites of involvement
CLP
Actinic Sun-exposed areas such as face, V-chest, hands
Annular Male genitalia (penis, scrotum), axilla, groin folds
Atrophic All parts of body especially lower extremetities
Erosive Soles of feet
Follicular Scalp
Guttate Trunk
Hypertrophic Anterior leg, ankles, and interphalangeal joints
Linear Leg-excoriated area
Papular Flexor surfaces (the main initial presentation)
Bullous Feet
Pigmentosus Sun exposed areas such as face, V-chest, hands
Pigmentosus-inversus Intertriginous and flexural areas
Nail involvement Fingernails and toenails
Palmoplantar involvement (1) Malleoli(2) Soles (internal plantar arch)
Lichen planopilaris (1) Vertex of scalp (classic type)(2) Frontal of scalp (FFA type)
Mucosal LP
Oral
Reticular
(1) Buccal mucosa and mucobuccal folds
(2) Lateral and dorsal tongue
(3) Gingiva and lips
Atrophic Attached gingiva
Hypertrophic Buccal mucosa
Erosive (1) Lateral and ventral portions of tongue(2) Buccal mucosa
Bullous Posterior and inferior areas of buccal mucosa
Plaque-like Dorsum of the tongue and buccal mucosa
Vulvovaginal
All subtypes Vaginal introitus, clitoris, clitoral hood, labia minora, and majora, vagina
Esophageal
(1) Proximal esophagus
(2) Proximal and distal esophagus
(3) Distal esophagus, strong possibility of concomitant mucosal involvement (80%)
FFA: frontal fibrosing alopecia, CLP: cutaneous lichen planus, FFA: frontal fibrosing alopecia, LP: lichen planus.
3.4. Diagnosis. The diagnosis of LP is based on the clinical
presentation and should be confirmed by biopsy, if suspected.
Histopathology is often conclusive, but in vesiculobullous
CLP or erosive OLP, direct immunofluorescence (DIF) stud-
ies can be an integral step in differentiating between LP
and other diseases [16]. DIF typically demonstrates globular
IgM deposition at the dermal-epidermal junction in LP [94].
Although the existence of fibrin deposition at the mucosal
submucosal interface and within vessels and the presence of
colloid bodies is highly sensitive for a diagnosis of LP, it lacks
specificity [95]. Indirect immunofluorescence and enzyme-
linked immunosorbent assays can also be helpful in reaching
a diagnosis [16].
3.4.1. Histopathology. LP is characterized by lichenoid inter-
face dermatitis. The classic histopathological features include
a dense, continuous, and band-like lymphohistiocytic infil-
trate at the dermal-epidermal junction and in the upper
dermis. Characteristically, the infiltrate disguises the dermal-
epidermal junction and makes it difficult to recognize the
basal layer at the early stages of the disease [96]. Epidermal
changes in LP lesions include irregular epidermal hyperplasia
with a jagged “sawtooth” appearance, compact hyperkeratosis
or orthokeratosis, foci of wedge-shaped hypergranulosis,
basilar vacuolar degeneration, slight spongiosis in the spinous
layer, and squamatization. The dermal papillae between
the elongated rete ridges are frequently dome shaped [97].
Necrotic keratinocytes can be observed in the basal layer
of the epidermis and at the dermal-epidermal junction.
Eosinophilic remnants of anucleate apoptotic basal cells may
also be found in the dermis and are referred to as “colloid
or civatte bodies” [1]. Whickham striae are usually seen in
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the areas of hypergranulosis [1]. Vacuolar degeneration at the
basal layer may be noted leading to focal subepidermal clefts
(Max Joseph spaces) [98]. Squamatization occurs as a result
of maturation and flattening of cells in the basal layer [1]. It
happens in areas ofmarked hypergranulosiswith prominence
of the sawtooth pattern of rete ridges [94]. Wedge-shaped
hypergranulosis can occur in the eccrine ducts (acrosy-
ringia) or hair follicles (acrotrichia) [99]. In the hyper-
trophic subtype, the associated hyperkeratosis, parakeratosis,
hypergranulosis, papillomatosis, acanthosis, and hyperplasia
markedly increased with thicker collagen bundles forming
in the dermis [94, 99]. Moreover, the rete ridges are more
elongated and rounded as opposed to the typical sawtooth
pattern [94]. In atrophic LP, loss of the rete ridges and dermal
fibrosis is prominent [99]. In vesiculobullous LP, the disease
progression is quicker. Hence, some of the distinctive features
such as hyperkeratosis, hypergranulosis, or dense lympho-
cytic dermal-epidermal infiltrate may not be present [99]. LP
lesion may resolve with residual hyperpigmentation caused
by a persistent increase in the number of melanophages in
the papillary dermis [96, 100].
In classic LPP, the bandlike lymphocytic infiltrate is
initially contained in the peribulge area including the
infundibulum and isthmus with sparing of the lower segment
of the hair follicle. The same follicular segments may exhibit
orthokeratosis, hypergranulosis, and follicular plugging [96].
The interfollicular epidermis is rarely affected [43]. LPP leads
to permanent hair loss due to the involvement of hair follicle
stem cells in the bulge. Fibrotic tissue can progressively
replace the hair follicles [101].
In mucosal lesions, the epithelial changes are less specific.
The rete ridges do not exhibit the characteristic pronounced
sawtooth pattern because normal oralmucosa exhibits parak-
eratosis with no granular layer [102]. Hence, OLP lesions
rarely exhibit orthokeratosis. OLP lesions are likely to be
more atrophic than acanthotic as compared to CLP [96].
Contrary to CLP and OLP, histolopathological findings in
genital erosive LP are less specific and often inconclusive
[70, 73].
3.4.2. Differential Diagnosis. The differential diagnosis of LP
is fairly broad and summarized in Table 2. An important
entity in the differential diagnosis of LP is lichenoid drug
reactions, which can virtually be indistinguishable from
cutaneous LP both clinically and histopathologically. Typ-
ically, lesions have a photodistribution in the absence of
oral mucosal involvement. The most commonly implicated
drugs are summarized in Table 3. Lichenoid drug reactions
characteristically exhibit parakeratosis, a dermal eosinophilic
infiltrate, and a perivascular lymphocytic infiltrate affecting
the reticular dermis. Epidermal changes are less common in
lichenoid drug eruptions when compared to classic LP [94].
However, a higher concentration of necrotic keratinocyte and
eosinophils in the infiltrate can be helpful in distinguishing
lichenoid drug reaction from cutaneous LP [103]. A lengthy
interval between the commencement of drug therapy and the
onset of lesions does not exclude a diagnosis of lichenoid drug
reaction [16]. Resolution of the lesions often occurs within
weeks to months after discontinuation of the offending drug
[104].
Lichenoid contact reaction is an important consideration
in the differential diagnosis of LP. Patch testing and challenge
testing can be utilized to properly identify the causal allergen.
As suggested in other patch test studies, one should interpret
positive patch test results to any particular allergen in the
context of its clinical relevance. In a retrospective cohort
study of patients with contact stomatitis or contact mucositis,
46/198 patients were diagnosed with OLP and had under-
gone patch testing. Fourteen out of forty-six patients (40%)
had identifiable contact hypersensitivity [105]. The main
triggering contact allergens involved in lichenoid contact
reactions are shown inTable 4.Metals can induce or aggravate
lichenoid contact reactions including silver-mercury amal-
gam fillings and other metals containing dental restorative
materials [106]. In a prospective study from Basque, such
lichenoid reactions were limited to old and corroded dental
fillings [107]. Even patients with negative patch test results are
likely to benefit from removing corroded restorations simply
by omitting themucosal irritation induced by them as a result
of Koebner’s phenomenon [108]. Food flavorings can also
induce lichenoid reactions including cinnamon, cinnamonic
aldehyde, and spearmint oil present in foods and dentifrices
[109, 110]. A rare lichenoid form of mycosis fungoides (MF)
can mimic CLP lesions. Lichenoid MF has more eosinophils,
mast cells, lymphocytic nuclear atypia, and more basilar
epidermotropism as compared to CLP [111]. Lichenoid MF
is extremely pruritic and has a poor prognosis. Therefore,
prompt diagnosis and management is crucial [111].
Resolving ashy dermatosis can be considered in the
differential diagnosis of hyperpigmented CLP lesions. Both
have similar histopathologic features. However, they can be
differentiated from each other by their color (blue-gray/ashy-
brown for ashy versus black-brown/violet-blue for LP), the
absence of erythematous borders in LP pigmentosus, and the
absence of itching in ashy dermatosis [112].
Lichen nitidus may be difficult to clinically distinguish
from generalized LP with a dense lymphohistiocytic infiltrate
on histopathology [113].
Differentiating between pseudopelade of Brocq and scar-
ring classic LPP can be challenging as they both have multi-
focal involvement of the vertex scalp although LPP presents
more frequently with perifollicular erythema and follicular
keratotic plugs than pseudopelade of Brocq [43, 114].There is
an ongoing debate as to whether pseudopelade of Brocq is a
subtype of LPP [47].
Lichen striatus has a clinical presentation similar to
linear LP. It presents as unilateral linear erythematous itchy
Papules in young adults and children. It is histopathologically
differentiated from linear LP by exhibiting more prominent
parakeratosis and spongiosis [115].
Distinguishing between the cicatricial alopecia induced
by LPP and discoid lupus erythematosus (DLE) can be
challenging. Unlike DLE, LPP often spares the interfollicular
epidermis [42]. Dermatoscopic examination can also be
helpful. Perifollicular scale and branching capillaries are
distinguishing dermatoscopic signs for LPP andDLE, respec-
tively [116].
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Table 2: LP differential diagnosis.
CLP
Papular classic Psoriasis, chronic cutaneous lupus erythematosus, lichen simplex chronicus, graft-versus-hostdisease, secondary syphilis, pityriasis rosea, lichenoid mycosis fungoides
Annular Granuloma annulare, tinea
Linear Lichen striatus, inflammatory linear verrucous epidermal nevus (ILVEN), linear psoriasis,linear Darier-White disease, nevus unius lateris
Hypertrophic Psoriasis, prurigo nodularis, lichenoid cutaneous amyloidosis, Kaposi sarcoma, lichen simplexchronicus, stasis dermatitis
Vesiculobullous Lichen planus pemphigoides, bullous pemphigoid, pemphigus vulgaris
LP pigmentosus Ashy dermatosis
Atrophic Lichen sclerosus et atrophicus, lupus, ashy dermatosis
Generalized Lichen nitidus, drug eruptions, guttate psoriasis, viral exanthems
LP of skin appendages
Follicular CLP (LPP) Lichen spinulosus
LPP induced cicatricial alopecia Pseudopelade of Brocq, follicular degeneration syndrome, androgenetic alopecia, chroniccutaneous lupus erythematosus
Nail CLP Brittle nails, lichen striatus, graft versus host disease, systemic amyloidosis, trauma,dyskeratosis congenital
Idiopathic atrophy of nails Hereditary anonychia, impaired peripheral circulation, epidermolysis bullosa
Trachyonychia Alopecia areata and psoriasis
Toenail LP Yellow nail syndrome
Erosive nail LP Blistering disease nail involvement
Mucosal LP
OLP
Leukoplakia, candidiasis, erythema multiforme, pemphigus vulgaris, bullous pemphigoid,
lichen sclerosus, secondary syphilis, bite trauma, lichen sclerosus et atrophicus, lupus, ashy
dermatosis
Vulvar LP Lichen sclerosis, valvovaginal blistering diseases
CLP: cutaneous lichen planus, LP: lichen planus, LPP: lichen planopilaris, OLP: oral lichen planus.
Granuloma annulare does not present with scale or
Wickham striae, but it may resemble annular LP [34].
Vesiculobullous CLP and LP pemphigoides are difficult to
differentiate. LP pemphigoides can be clinically distinguished
by amore generalized distribution, more extensive blistering,
and a more chronic course [117].
Blistering diseases and lupus erythematous are on the list
of differential diagnoses of OLP. The differential diagnosis of
OLP from other diseases is particularly difficult in the non-
reticulated forms often necessitating biopsy and DIF studies
[16]. Erosive/ulcerative OLP should be distinguished from
mucous membrane pemphigoid. The presence of whitish
hyperkeratotic striations and skin involvement are important
differentiating features [118]. The DIF pattern of a pem-
phigoid lesion will most often include linear IgG and C3 and
rarely, IgM at the basement membrane level. Table 5 presents
the DIF patterns of the differential diagnoses of LP.
Vulvar mucosal LP can be misdiagnosed as lichen sclero-
sis or vulvovaginal blistering diseases. The classic Wickham
striae and histopathologic examination can be helpful in
making the distinction.
3.5. Immunopathogenesis. LP is a T-cell-mediated autoim-
mune disease. Inflammatory cells involved in this process
consist of T helper and T cytotoxic lymphocytes, natural
killer (NK) cells, and dendritic cells. T-cell activation is
central to the pathogenesis of LP. Cytotoxic T-cell infiltration
into the epithelium results in apoptotic basal keratinocytes.
Theoretically, it may be induced by CXCR3 and CCR5
mediated signaling pathways initiated by both T-cells and
keratinocytes [119]. In the early stages, T-cells predominantly
home in the deeper layers of the epidermis and at the dermal-
epidermal junction [119]. CCR5 related chemokines as well as
CXCR3-targeting chemokines are significantly overexpressed
in LP lesions in concert with the increased trafficking of
mononuclear cells to the interface region [120, 121]. This
correlation or coincidence suggests that both keratinocyte
induced- and self-recruiting mechanisms are involved in T-
cell migration within LP lesions. Furthermore, Langerhans
cell recruitment is induced by CCR6 related chemokines
[119]. Activated T-cells stimulate the T helper type 1 (Th1)
response, thus resulting in keratinocyte removal by immune
cells [120].
The TH1 dominance in LP patients is partly regulated
through toll-like receptor (TLR) 2 upregulation [120]. TLR
is mainly involved in innate immunity but can also trigger
adaptive immunity. TLR2 activation is known to induce TH1
activation. However, there is a contrasting result from a
study suggesting downregulation of TLR2 and upregulation
of TLR4 in OLP patients [122]. Moreover, in OLP patients,
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Table 3: Drugs responsible for lichenoid reaction.
Anticholinergics
(i) Solifenacin
Anticonvulsants
(i) Carbamazepine
(ii) Oxcarbazepine
(iii) Phenytoin
(iv) Valproate sodium
Antidiabetics
(i) Chlorpropamide
(ii) Glyburide
(iii) Glipizide
(iv) Insulin
(v) Tolazamide
(vi) Tolbutamide
Antidiarrheals
(i) Bismuth
Antigout
(i) Allopurinol
Antihistamine drugs
(i) Cinnarizine
(ii) Iodides
Anti-inflammatory
drugs
(i) Aspirin
(ii) Diflunisal
(iii) Ibuprofen
(iv) Indomethacin
(v) Leflunomide
(vi) Mesalamine
(vii) Naproxen
(viii) Rofecoxib
(ix) Sulindac
(x) Sulfasalazine
(xi) Tolbutamide
Antimalarials
(i) Chloroquine
(ii) Hydroxychloroquine
(iii) Pyrimethamine
(iv) Quinidine
(v) Quinine
Antimicrobials
Antibiotics
(i) Para-aminosalicylic
acid
(ii) Sulphamethoxazole
(iii) Tetracycline
Antimycobacterials
(i) Aminosalicylate
sodium
(ii) Dapsone
(iii) Ethambutol
(iv) Isoniazid
(v) Rifampin
(vi) Streptomycin
Antifungals
(i) Amphotericin B
(ii) Griseofulvin
(iii) Ketoconazole
Antihelminthic
(i) Levamisole
Cardiovascular drugs
(i) Atenolol
(ii) Captopril
(iii) Doxazosin
(iv) Diazoxide
(v) Enalapril
(vi) Labetalol
(vii) Metoprolol
(viii) Methyldopa
(ix) Nebivolol
(x) Nicorandil
(xi) Nifedipine
(xii) Prazosin
(xiii) Procainamide
(xiv) Propranolol
(xv) Quinidine
(xvi) Terazosin
Diuretics
(i) Chlorothiazide
(ii) Furosemide
(iii) Hydrochlorothiazide
(iv) Spironolactone
Immunomodulatory and
biological therapies
(i) Adalimumab
(ii) Dactinomycin
(iii) Etanercept
(iv) Gold salts
(v) Imatinib mesylate
(vi) Infliximab
(vii) Interferon-𝛼
(viii) Penicillamine
(ix) Tacrolimus
Lipid lowering drugs
(i) Gemfibrozil
(ii) Orlistat
(iii) Pravastatin
(iv) Simvastatin
Metals
(i) Arsenic
Psychiatricdrugs
(i) Antipsychotics
(Chlorpromazine,
Levomepromazine,
Methopromazine, Thioridazine)
(ii) Benzodiazepines
(Lorazepam)
(iii) Imiquimod
(iv) Lithium
(v) Selective serotonin reuptake
inhibitor (Escitalopram)
(vi) Tricyclic antidepressants
(Amitriptyline, Imipramine)
Retinoids
(i) Isotretinoin
Table 3: Continued.
Antiparkinsoniandrugs
(i) Trihexyphenidyl
Antiretrovirals
(i) Zidovudine
Chemotherapy drugs
(i) Hydroxyurea
Other medications
(i) Amiphenazole
(ii) Clopidogrel
(iii) Penacillamine
(iv) Palifermin
(v) Mercapto-propionylglycine
(vi) Misoprostol
(vii) Nandrolene
(viii) furyl-propionate
(Demelon)
(ix) Norflex
(x) Omeprazole
(xi) Pyrithioxin
(xii) Sildenafil
(xiii) Tiopronin
Modified from Schlosser [16].
Table 4: Possible contact allergens to induce lichenoid contact
reactions.
Dental restoration/
crowning materials
Beryllium, cobalt, copper, chromium, gold,
indium, mercury, nickel, palladium, silver,
tin, zinc, composite resins, ceramics
(porcelain), ethylene glycol dimethacrylate,
titanium
Flavorings
Menthol oil, peppermint, cinnamon,
spearmint, balsam of Peru, vanillin, jasmine
absolute, lemon oil, eugenol
Modified from Schlosser [16].
TLR4 and TLR9 are upregulated in the superficial and basal
layers, respectively [123].
NK cells can migrate to LP lesions more frequently than
to healthy skin [124].Theymay contribute to the pathogenesis
of LP due to their cytotoxic activity and their ability to secrete
proinflammatory cytokines [124].
One of the main pathogenetic mechanisms of LP is
increased apoptosis of keratinocytes and decreased apoptosis
of T-cells [125]. Activated cytotoxic T-cells can upregulate
the Fas ligand and induce keratinocyte apoptosis in the
suprabasal cell layer by binding to Fas on the surface of
keratinocytes [126]. NK cells and cytotoxic T-cells may also
induce apoptosis via the granzyme B/perforin pathway. This
autodestructive immunologic mechanism is more abundant
in OLP than CLP [127]. The altered immune response results
in apoptosis of basilar keratinocytes and ultimately leads to
liquefaction of the entire basal layer.These apoptotic changes
may also be a reflection of the disease activity [128].
Ragaz and Ackerman noted an increased number of
Langerhans cells in the epidermis very early in the disease
process [99]. These cells function to present the autoantigens
or foreign antigens to T-cells prior to T-cell activation.
Langerhans cells are more prevalent in OLP lesions than
healthy oral mucosa and the degree of migration of these
cells from the superficial layers to the basal layer may be a
predictor of disease chronicity [129].
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Table 5: The pattern of DIF results of potential differential diagnoses of lichen planus.
Differential DIF pattern
Lichen planus Globular IgM and fibrin deposition at BMZ
Aphthous ulcers Negative
Bullous pemphigoid Linear C3, IgG at BMZ, less common IgA
Chronic ulcerative stomatitis Speckled or granular perinuclear IgG in the lower third and basal layer of epithelium
Dermatitis herpetiformis Granular IgA at BMZ with concentration at the papillary tips
Discoid lupus erythematosus Linear band or continuous granular IgG, IgA, IgM, and C3 at BMZ
Epidermolysis bullosa acquisita Linear IgG and C3 at BMZ
Erythema multiforme Negative
Hailey-Hailey disease Negative
Lichen nitidus Negative
Linear IgA bullous dermatosis Linear IgA at BMZ, less common IgG, IgM, and C3
Mucous membrane pemphigoid Linear IgG and C3 at BMZ, less common IgA, IgM, and/or fibrin
Paraneoplastic pemphigus Intercellular IgG and C3 with or without BMZ involvement
Pemphigus vulgaris Intercellular IgG (IgG1 and IgG4) in “chicken wire pattern,” less common C3 and IgM
Systemic lupus erythematosus Linear band or continuous granular IgG, IgA, IgM, and C3 at BMZ
BMZ: basement membrane zone; DIF: direct immunofluorescence; Ig: immunoglobulin.
4. Etiology and Risk Factors
4.1. Immunogenetic Factors. LP is a complex disease and
thus can be caused or triggered by genetic malfunction
and/or environmental factors. The existence of familial cases
of LP may suggest a possible genetic predisposition [130,
131]. Gene polymorphisms of different HLA markers as well
as the inflammatory cytokines and chemokines have been
associated with the presence of LP (Table 6). The causality
of these polymorphisms, although unclear, supports the
autoantigen hypothesis.
4.2. Clinical Factors. Associated factors and disease condi-
tions seen in LP include but are not limited to stress/anxiety,
hepatitis C virus (HCV), autoimmune diseases, internal
malignancies, dyslipidemia, and viral infections. Anxiety is
a well-established risk factor or accompanying factor in LP
patients [132]. Some studies have indicated that stressful
events can induce LP lesions in otherwise healthy individuals.
In a case-control study, more than 67% of LP patients
experienced a stressful event while about 21% of matched
healthy controls experienced such events [133]. Other studies
more or less indicate a similar trend for stress, anxiety, and
depression [134, 135]. Table 7 summarizes the coexistence of
some clinical conditions and LP.
We performed a meta-analysis to find the potential
association between LP and HCV including all studies in
previously published meta-analyses [136–138] and new stud-
ies [139–143], which investigated the prevalence of HCV in
LP patients compared with a control population. Based on
data pooling of 64 studies, LP patients have 5.58 times the
odds of having concurrent HCV infection than the control
population (95% CI: 3.72–8.38, 𝑃 < 0.05).
In an attempt to investigate the role of HPV in the
pathogenesis of OLP, Syrja¨nen et al. [144] performed a meta-
analysis. They found statistically remarkable and significant
odds ratios for HPV, in general, and HPV-16 (5.12 (95%
CI: 2.40–10.93) and 5.61 (95% CI: 2.42–12.99), resp.). This
finding suggests that HPV has a higher prevalence in OLP
patients than the normal population; it may have a role in the
malignant transformation of OLP lesions [145]. Erosive OLP
and hypertrophic CLP are considered as the main subtypes
with malignant potential [20, 146].
A systematic search revealed three studies [189–191] that
compared the prevalence of the transfusion transmitted virus
or Torque tenovirus (TTV) in LP versus disease-control
patients or healthy volunteers. TTV is the only member of
Anelloviridae [192]. After performing a meta-analysis using
two studies [190, 191], there was no significant difference
between LP and healthy control groups (odds ratio of 1.13
[95% CI: 0.67–1.89], 𝑃 > 0.05). Fehe´r et al. [190] recently
showed that genogroup 1 TTV—not TTV in general—is
significantly more common in OLP patients (10.1%) when
compared to the control group (1.4%). This group hypothe-
sized that genogroup 1 TTV is correlated with the immuno-
inflammatory response in OLP patients. They also evaluated
the subtypes and genotypes of TTV in the aforementioned
patients and noted some differences in OLP lesions and
normal skin samples from the same patients [193].
While the varicella zoster virus is rare in OLP patients
[194, 195], a recent study noted a significant role for the virus
in zosteriform LP but not in linear LP [196].
LP patients are at increased risk of developing dyslipi-
demia, with an adjusted odds ratio of 2.85 (95% CI, 1.33–
5.09; 𝑃 = 0.001) [197]. However, patients with hyperglycemia
and/or hypertension are not at risk [197].
5. Quality of Life
Quality of life questionnaires are easy and practical tools to
quantify the impact of a disease based on the patient’s percep-
tion. There are a large number of general and dermatology-
related quality of life questionnaires including the Derma-
tology Life Quality Index (DLQI), which is a widely used
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Table 6: Suggested gene polymorphisms that are associated with LP.
Gene polymorphism of immune-related genes
IFN gamma [147, 148]
TNF [149, 150]
TNF-𝛼 receptor 2 [151]
IL-4 (only nonerosive OLP) [147]
IL-6 [150]
Haplotype IV of IL-10 [152]
IL-18 [153]
Tumor suppressor genes (e.g., P53) [154, 155]
HLA-A3 (In a Swedish population with LP [156] and two British populations with LP [157] and with familial LP [158])
HLA-A5 (in a British population with LP [157])
HLA-B7 (in a British population with familial LP [158], another study supported against [159])
HLA-B8 (OLP) [2], a study supported against [159]
HLA-B15 (in a Croatian population with OLP) [160]
HLA-B18 inverse association with OLP in a Croatian population [160]
HLA-Bw35 (CLP) [2]
HLA-Bw57 (in a British population with OLP) [161]
HLA-BW61 (in a Japanese population with OLP) [162]
HLA-DR1 (in wide range of ethnicities) [163–167], in a British population with CLP [167], in an Italian population with LP [168],
and in an Arab population with CLP [166]
HLA-DRB1∗0101 (in a Sardinian population in Italy with CLP [169] and also with LP in a Mexican Mestizo population [169] and in
a British population with CLP [167]),
HLA-DR2 (in an Israeli-Jewish population with erosive OLP) [170],
HLA-DR3 (in a Swedish population with erosive OLP) [171]
HLA-DR9 (in Chinese population with erosive OLP) [172]
HLA-DRW9 (in a Japanese population with OLP) [162]
HLA-DR10 (in an Arab population with CLP) [166]
HLA-DQ1 (in a British population with CLP, [167] inverse association with OLP in a British population [161]
HLA-DQB1∗0201 (with vulvovaginal-gingival syndrome in two British populations) [81, 173]
HLA-Te22 (in a Chinese population with erosive OLP) [172]; also it is highly associated with positive antinuclear antibodies in
erosive OLP patients [174]
rs2372736, defined at the chromosome 3p14-3q13 [175]
Gene polymorphism of other genes
Oxidative stress [176–179]
PGE2 [180]
Antithyroglobulin, antithyroid microsomal autoantibody, T3, T4 [181–183]
Prothrombin [184]
Epigenetic-associated genes (DNMT3B) [185]
miRNA-146a [186] and miRNA-155 [186, 187]
Nuclear factor-kappa B p65 [188]
The ones in bold are considered more prevalent than the others.
dermatology specific quality of life instrument [276]. LP was
comparable to psoriasis with regard to Dermatology Life
Quality Index (DLQI) scores of 9.60 ± 7.32 versus 9.50 ± 6.10,
respectively. Additionally, OLP patients had a significantly
higher DLQI score when compared to CLP patients (13.27
± 8.05 versus 7.47 ± 6.11) [277]. The Oral Health Impact
Profile (OHIP) is a 49 item quality of life questionnaire to
evaluate the social impact of oral disorders which is based on
theoretical hierarchy of oral health outcomes [278]. OLP
was found to have a significant impact on psychological
discomfort and social disability, using OHIP 49 item ques-
tionnaire [279]. Furthermore, OLP seems to have a higher
impact on patients’ quality of life than recurrent aphthous
stomatitis but lower impact as compared to oral bullous
diseases [280]. There is also a correlation between increase
in pain evaluated by visual analogue scoring and poor oral
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Table 7: Clinical associations of LP.
Cutaneous diseases
Chronic graft versus host disease [198–200]
Alopecia areata [201, 202]
Pemphigus vulgaris [203]
Paraneoplastic pemphigus [204]
Dermatitis herpetiformis [205, 206]
Bullous pemphigoid [207–209]
Atopic dermatitis [23]
Psoriasis [210]
Vitiligo [211–213]
Morphea [214–217]
Dermatomyositis [218]
Lichen sclerosus et atrophicus [215, 219–221]
Other diseases
Liver disease [201, 222] (primary biliary cirrhosis, [223–225]
primary sclerosing cholangitis [226])
HCV infection [138, 142, 227]
EBV infection [228–230]
HPV infection [145, 230–232]
HHV-7 [230, 233, 234]
Ulcerative colitis [201, 202]
Chronic gastritis, Helicobacter pylori [77, 235–237]
Dyslipidemia [197, 238, 239]
Anxiety [132, 135, 240–250] or stress [20, 251]
Depression [132, 134, 135, 241, 242, 244–250, 252–255]
Celiac disease [256–259]
Myasthenia gravis and thymoma [260–266],
Systemic lupus erythematosus [267–270]
Sjo¨gren’s syndrome [271, 272]
Multiple sclerosis [273]
Hypothyroidism [274]
Hashimoto thyroiditis
Verruciform xanthoma [275]
health-related quality of life in patients with LP [281]. Patients
with erosive OLP or generalized LP may have poor quality of
life because of the associated pain and discomfort.
5.1. Prognosis. Typically, CLP lesions resolve within 6months
to a year. However, the hypertrophic variant, if left untreated,
tends to persist for years. Untreated reticular OLP has a
chronic or progressive nature, usually without complete
resolution. LP can also have a recurrent pattern. Patients with
erosive LP may experience changes in location and severity
of the disease with waxing and waning cycles of concurrent
healing and lesion formation. Although generalized LP tends
to heal faster than other variants, it has a greater likelihood
of relapse [2]. LPP can be progressive in its course with
destruction of hair follicles leading to atrophic cicatricial
alopecia [43].
5.2. Carcinogenic Transformation. Thecarcinogenic potential
of OLP lesions has been a longstanding topic of debate.
When loss of heterozygosity and microsatellite instability
were investigated as two of the main indicators for malignant
transformation, OLP was not different from benign fibroma,
but it was significantly different from low-grade oral
dysplasia, high-grade oral dysplasia, and oral SCC [282].
Vered et al. clearly suggested a widespread proinflammatory
response rather than a protumorigenic response [283].
Similar to other malignancies, the elderly are at increased
risk for developing SCC [284] and tend to have more severe
forms of the disease [285].
The epidemiology surrounding OLP and its inherent risk
of oral squamous cell carcinoma remains poorly defined.
A question, that has yet to be answered, is whether the
associated risk of malignant transformation is intrinsic to
the OLP lesions or as a result of the patient’s immune
response or genetic background.There is no proper surrogate
biomarker for OLP malignant transformation. Shi et al.
suggested the co-expression of podoplanin and ATP-binding
cassette transporter G2 (ABCG2) as a higher prognostic
marker with a significant odds ratio (25.24, 95% CI: 4.48–
142.27, 𝑃 < 0.001) [284]. Unfortunately, podoplanin is not
sensitive or specific, as it can be expressed even in normal skin
[286]. Additionally, ABCG2 is expressed in various organs
and has a major role in tissue repair [287] in addition to
chemoresistance of different tumors [288]. Another marker,
c-Jun, a member of activating protein-1 transcription factor
family, was present in 11 out of 12 LP patients and in all SCC
patients while not expressed remarkably in normal patients.
These transcription factors contribute to cell proliferation and
thus they may be indications of LP’s carcinogenic potential
[289]. These reports should be interpreted cautiously due to
the small sample size and lack of prospective follow-up. The
literature is still inconclusive in this regard except for the fact
that it seems improbable that OLP is inherently carcinogenic
[290].
The malignant transformation rate of vulvar LP and
esophageal LP seems to be 1.1% [73] and 5.5% [76], respec-
tively. In a cohort study with no healthy controls and without
correcting the odds ratio for premalignant viral diseases, 8 of
327 OLP patients (2.4%) developed oral SCC in previously
affected areas. Interestingly, this was not correlated with
immunosuppressive therapy in those patients [291]. The
transformation ratio for OLP lesions varies from 0.8% in
an American population [20] to more than 5% in an Italian
cohort [292]. This ratio appears to be no more than 1% for
OLP over 5 years [293]. Nonetheless, this estimated rate does
not match the prevalence of OLP and oral cancer. Indeed, an
OLP prevalence of 1% and a transformation rate of 0.2% per
year would mean that almost every single oral SCC should
arise from an OLP lesion. Hence, this theory was refuted as
few accompanying OLP lesions were detected in oral SCC
patients [293–296]. Further investigation of whether chronic
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LP is a premalignant condition would necessitate large-scale
prospective cohort studieswith a long-term follow-up period.
6. Conclusions
LP is a T-cell mediated disease. The prevalence of LP is less
than 5% with no evident sexual predilection. The chronic
and often erosive nature of LP can have detrimental effects
on patients’ quality of life. Erosive-ulcerative OLP lesions
tend to become painful and chronic and vulvar LP may
interfere with sexual intercourse and can be associated with
significant psychological and physical morbidity. HCV and
HPV are more prevalent in LP patients compared to the
normal population.The carcinogenic potential ofOLP lesions
remains debatable.
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